This review demonstrates anticancer effects of metformin in breast cancer, suggesting biomarker-driven strategies for improved outcomes.
Metformin and its derivatives exert dual anticancer effects by modulating systemic insulin signaling and targeting tumor-intrinsic pathways. Nevertheless, inconsistencies between preclinical efficacy and clinical outcomes highlight the need for biomarker-guided approaches and deeper investigation into tumour-specific metabolic contects. These complementary mechanisms highlight their potential in precision BC therapy, warranting biomarker-driven studies and optimized therapeutic combinations.
No takes yet. Share an insight, caveat, or question.
Alim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: